YUHSpace: Dept. of Internal Medicine (내과학교실)

YUHSpace

BROWSE

YUHSpace1. College of Medicine (의과대학)Dept. of Internal Medicine (내과학교실)

Dept. of Internal Medicine (내과학교실)

Researcher List

Keyword Cloud

Journal Categories

Hot Articles

Trastuzumab in combination with chemotherapy versus chemotherapy alone f...

Yung-Jue Bang ; Eric Van Cutsem ; Andrea Feyereislova ; Hyun C Chung ; Lin Sh... LANCET, Vol.376(9742) : 687-697, 2010

Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer

Jean-Charles Soria ; Yuichiro Ohe ; Johan Vansteenkiste ; Thanyanan Reungwetw... NEW ENGLAND JOURNAL OF MEDICINE, Vol.378(2) : 113-125, 2018

Cetuximab and chemotherapy as initial treatment for metastatic colorecta...

Eric Van Cutsem ; Claus-Henning Köhne ; Erika Hitre ; Jerzy Zaluski ; Chung-R... NEW ENGLAND JOURNAL OF MEDICINE, Vol.360(14) : 1408-1417, 2009

PDF Read more

This table browses all dspace content
Issue Date	Title	Journal Title
2022	Development and Roll-Out of A Coronavirus Disease 2019 Clinical Pathway for Standardized Qualified Care in Public Hospitals in Korea	INFECTION AND CHEMOTHERAPY
2022	Health-related quality-of-life outcomes in patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab or everolimus versus sunitinib (CLEAR): a randomised, phase 3 study	LANCET ONCOLOGY
2022	Modified endoscopic vacuum therapy: Are we ready for prime time? Response	GASTROINTESTINAL ENDOSCOPY
2022	노인의 운동참여 동기 유형과 관련 요인	Journal of Korea Gerontological Society(한국노년학)
2022	Relationship Between Coronary Artery Calcium and Atherosclerosis Progression Among Patients With Suspected Coronary Artery Disease	JACC-CARDIOVASCULAR IMAGING
2022	Safety and efficacy of nilotinib in adult patients with chronic myeloid leukemia: a post-marketing surveillance study in Korea	BLOOD RESEARCH
2022	공익적 임상연구를 위한 연구설계 결정과정: 환자중심 의료기술 최적화 연구(PACEN) 과제화를 중심으로	Journal of Health Technology Assessment(보건의료기술평가)
2022	IM156, a new AMPK activator, protects against polymicrobial sepsis	JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
2022	Total Lesion Glycolysis on 18F-FDG PET/CT Is a Better Prognostic Factor Than Tumor Dose on 90Y PET/CT in Patients With Hepatocellular Carcinoma Treated With 90Y Transarterial Radioembolization	CLINICAL NUCLEAR MEDICINE
2022	Co- occurring HER2 and PD-L1 expression in patients with HER2-positive trastuzumab-refractory gastric cancer (GC)/gastroesophageal junction adenocarcinoma (GEJA): Biomarker analysis from the trastuzumab deruxtecan (T-DXd) DESTINY-Gastric03 trial	ANNALS OF ONCOLOGY
2022	Outcomes by primary tumour location in patients with advanced biliary tract cancer treated with durvalumab or placebo plus gemcitabine and cisplatin in the phase 3 TOPAZ-1 study	ANNALS OF ONCOLOGY
2022	Elevated On-Treatment Diastolic Blood Pressure and Cardiovascular Outcomes in the Presence of Achieved Systolic Blood Pressure Targets	KOREAN CIRCULATION JOURNAL
2022	Analysis of risk factors for recurrence of distal bile duct cancer without lymph node metastasis after curative resection: Is adjuvant therapy really required?	ANNALS OF ONCOLOGY
2022	RISK OF SYSTEMIC LUPUS ERYTHEMATOSUS FLARES ACCORDING TO THE POSITIVITY OF AUTOANTIBODIES	ANNALS OF THE RHEUMATIC DISEASES
2022	A scoring model to predict the clinical outcome of self-expandable metal stents in patients with colorectal obstruction due to extracolonic malignancy	ANNALS OF ONCOLOGY
2022	A phase 2, multi-center, open-label study of cinrebafusp alfa (PRS-343) in patients with HER2-high and HER2-low gastric or gastroesophageal junction (GEJ) adenocarcinoma	ANNALS OF ONCOLOGY
2022	Phase 2 study of pembrolizumab-based combination therapy in patients with microsatellite instability-high or mismatch repair-deficient stage IV colorectal cancer	ANNALS OF ONCOLOGY
2022	Phase 1 trial of vibostolimab plus pembrolizumab for PD-1/PD-L1 inhibitor-naive advanced gastric cancer: The KEYVIBE-001 trial	ANNALS OF ONCOLOGY
2022	The Assessment and Outcomes of Crossmatching in Lung Transplantation in Korean Patients	JOURNAL OF KOREAN MEDICAL SCIENCE
2022	Long-Term Efficacy and Safety of Entrectinib in ROS1 Fusion-Positive NSCLC	JTO Clinical and Research Reports